|drug1425||Growth Mindset Wiki||1.00|
|D002318||Cardiovascular Diseases NIH||0.19|
There is one clinical trial.
COVID-19 is associated with complications including ARDS and myocardial injury, which informs prognosis and patient outcome. The laboratory plans to perform immunophenotyping of peripheral T-cells in patients with COVID-19 and complications (ARDS, ITU admission, myocardial injury) and map this against clinical patient outcomes. The aim is to determine if there is a specific T-cell immunophenotype associated with COVID-19 and/or complications, which can be used to inform prognosis and potential therapies.
Description: T-cell immunophenotypeMeasure: T-cell immunophenotype Time: 12 months from enrollment
Description: death, survival to dischargeMeasure: Mortality Time: 12 months from enrolment
Description: Admission to the intensive careMeasure: ITU admission Time: 12 months from enrolment
Description: Defined by troponin rise to >99th centileMeasure: Myocardial injury Time: 12 months from enrolment
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports